» Articles » PMID: 38436541

Pyroglutamylation Modulates Electronic Properties and the Conformational Ensemble of the Amyloid β-peptide

Overview
Journal Proteins
Date 2024 Mar 4
PMID 38436541
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that is characterized by the formation of extracellular amyloid-β (Aβ) plaques. The underlying cause of AD is unknown, however, post-translational modifications (PTMs) of Aβ have been found in AD patients and are thought to play a role in protein aggregation. One such PTM is pyroglutamylation, which can occur at two sites in Aβ, Glu3 and Glu11. This modification of Aβ involves the truncation and charge-neutralization of N-terminal glutamate, causing Aβ to become more hydrophobic and prone to aggregation. The molecular mechanism by which the introduction of pyroglutamate (pE) promotes aggregation has not been determined. To gain a greater understanding of the role that charge neutralization and truncation of the N-terminus plays on Aβ conformational sampling, we used the Drude polarizable force field (FF) to perform molecular dynamics simulations on Aβ and Aβ and comparing their properties to previous simulations of Aβ. The Drude polarizable FF allows for a more accurate representation of electrostatic interactions, therefore providing novel insights into the role that charge plays in protein dynamics. Here, we report the parametrization of pE in the Drude polarizable FF and the effect of pyroglutamylation on Aβ. We found that Aβ and Aβ alter the permanent and induced dipoles of the peptide. Specifically, we found that Aβ and Aβ have modification-specific backbone and sidechain polarization response and perturbed solvation properties that shift the Aβ conformational ensemble.

References
1.
Marksteiner J, Humpel C . Beta-amyloid expression, release and extracellular deposition in aged rat brain slices. Mol Psychiatry. 2007; 13(10):939-52. DOI: 10.1038/sj.mp.4002072. View

2.
Jang H, Arce F, Ramachandran S, Capone R, Azimova R, Kagan B . Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc Natl Acad Sci U S A. 2010; 107(14):6538-43. PMC: 2851998. DOI: 10.1073/pnas.0914251107. View

3.
Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski J . Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol. 2006; 112(2):163-74. DOI: 10.1007/s00401-006-0077-5. View

4.
Nath S, Buell A, Barz B . Pyroglutamate-modified amyloid β(3-42) monomer has more β-sheet content than the amyloid β(1-42) monomer. Phys Chem Chem Phys. 2023; 25(24):16483-16491. DOI: 10.1039/d2cp05961d. View

5.
Moro M, Phillips A, Gaimster K, Paul C, Mudher A, Nicoll J . Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease. Acta Neuropathol Commun. 2018; 6(1):3. PMC: 5753481. DOI: 10.1186/s40478-017-0505-x. View